Comparative mortality risks of antipsychotic medications in community-dwelling older adults

British Journal of Psychiatry

Volumn 205, Issue 1, 2014, Pages 44-51

  Gerhard, T ^a,b   Huybrechts, K ^c   Olfson, M ^d,e   Schneeweiss, S ^c   Bobo, W V ^f   Doraiswamy, P M ^g   Devanand, D P ^d,e   Lucas, J A ^a   Huang, C ^a   Malka, E S ^a   Levin, R ^c   Crystal, S ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Department of Psychiatry College of Physicians and Surgeons Columbia University ^*  (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COMMUNITY LIVING; COMORBIDITY; COMPARATIVE STUDY; DELIRIUM; DEMENTIA; DEPRESSION; DOSE RESPONSE; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MORTALITY; NEOPLASM; OUTCOME ASSESSMENT; PRESCRIPTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RESPIRATORY SYSTEM; RISK ASSESSMENT; SCHIZOPHRENIA; VERY ELDERLY; DEMOGRAPHY; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDY; RISK;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MORTALITY; PSYCHOTIC DISORDERS; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES; RISK;

EID: 84901443823     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.112.122499     Document Type: Article

References (52)

1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebocontrolled trials. JAMA 2005; 294: 1934-43.
2. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353: 2335-41.
3. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14: 191-210.
4. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306: 1359-69.
5. Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 2011; 10: 35-43.
6. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 2006; 7: 492-500.
7. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) 2009; 28: w770-81.
8. Shah SM, Carey IM, Harris T, Dewilde S, Cook DG. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry 2011; 26: 423-34.
9. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146: 775-86.
10. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176: 627-32.
11. Liperoti R, Onder G, Landi F, Lapane KL, Mor V, Bernabei R, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 2009; 70: 1340-7.
12. Rochon PA, Normand SL, Gomes T, Gill SS, Anderson GM, Melo M, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008; 168: 1090-6.
13. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007; 164: 1568-76.
14. US Food and Drug Administration. Information on Conventional Antipsychotics. US Department of Health and Human Services (http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/ DrugSafetyInformationforHealthcareProfessionals/PublicHealthAdvisories/ ucm107211).
15. US Food and Drug Administration. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. US Department of Health and Human Services (http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171) .
16. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010; 170: 96-103.
17. Gerhard T, Lucas J, Olfson M, Hoover D, Kalay E, Crystal S. Effect of regulatory warnings on antipsychotic prescribing for nursing home residents with dementia. Pharmacoepidemiol Drug Saf 2008; 17: S120.
18. Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 2011; 68: 190-7.
19. Medicines and Healthcare Products Regulatory Agency. Drug Safety Update March 2009: vi. MHRA 2009
20. Jano E, Johnson M, Chen H, Aparasu RR. Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Curr Med Res Opin 2008; 24: 709-16.
21. Kamble P, Sherer J, Chen H, Aparasu R. Off-label use of second-generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv 2010; 61: 130-6.
22. Child A, Clarke A, Fox C, Maidment I. A pharmacy led program to review anti-psychotic prescribing for people with dementia. BMC Psychiatry 2012; 12: 155.
23. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012; 344: e977.
24. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2011; 169: 71-9.
25. Rossom RC, Rector TS, Lederle FA, Dysken MW. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia. J Am Geriatr Soc 2010; 58: 1027-34.
26. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731-7.
27. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
28. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-7.
29. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2009; 67: 255-62.
30. Doody MM, Hayes HM, Bilgrad R. Comparability of national death index plus and standard procedures for determining causes of death in epidemiologic studies. Ann Epidemiol 2001; 11: 46-50.
31. Fillenbaum GG, Burchett BM, Blazer DG. Identifying a national death index match. Am J Epidemiol 2009; 170: 515-8.
32. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-10). WHO 1992
33. Sesso HD, Gaziano JM, Glynn RJ, Buring JE. Value of an Endpoints Committee versus the use of nosologists for validating cause of death. Contemp Clin Trials 2006; 27: 333-9.
34. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512-22.
35. Preskorn SH. Clinical relevance of relative receptor binding affinity: quetiapine and ziprasidone as examples. J Psychiatr Pract 2007; 13: 393-8.
36. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 2004; 9 (suppl 11): 6-14.
37. Curran S, Turner D, Musa S, Wattis J. Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups. Int J Geriatr Psychiatry 2005; 20: 842-7.
38. Huybrechts KF, Brookhart MA, Rothman KJ, Silliman RA, Gerhard T, Crystal S, et al. Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients. Am J Epidemiol 2011; 174: 1089-99.
39. Fillit H, Geldmacher DS, Welter RT, Maslow K, Fraser M. Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias. J Am Geriatr Soc 2002; 50: 1871-8.
40. Lin PJ, Kaufer DI, Maciejewski ML, Ganguly R, Paul JE, Biddle AK. An examination of Alzheimer's disease case definitions using Medicare claims and survey data. Alzheimers Dement 2010; 6: 334-41.
41. Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord 2009; 23: 306-14.
42. Newcomer R, Clay T, Luxenberg JS, Miller RH. Misclassification and selection bias when identifying Alzheimer's disease solely from Medicare claims records. J Am Geriatr Soc 1999; 47: 215-9.
43. Corbett A, Ballard C. Antipsychotics and mortality in dementia. Am J Psychiatry 2012; 169: 7-9.
44. McCleery J, Fox R. Antipsychotic prescribing in nursing homes. BMJ 2012; 344: e1093.
45. Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry 2012; 169: 900-6.
46. National Institute for Health and Clinical Excellence/Social Care Institute for Excellence. Dementia - Supporting People with Dementia and Their Carers in Health and Social Care. Clinical Guidance CG42. NICE/SCIE 2006
47. Ayalon L, Gum AM, Feliciano L, Arean PA. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med 2006; 166: 2182-8.
48. Cohen-Mansfield J, Thein K, Marx MS, Dakheel-Ali M. What are the barriers to performing nonpharmacological interventions for behavioral symptoms in the nursing home. J Am Med Dir Assoc 2012; 13: 400-5.
49. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009; 5: 245-55.
50. Mitka M. CMS seeks to reduce antipsychotic use in nursing home residents with dementia. JAMA 2012; 308: 119-21.
51. Banerjee S. The Use of Antipsychotic Medication for People With Dementia: Time for Action. A Report for the Minister of State for Care Services. Department of Health 2009
52. Pollock BG, Mulsant BH. Between Scylla and Charybdis: antipsychotic and other psychotropic medications in older nursing home residents. CMAJ 2011; 183: 778-9.